Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proliposomal paclitaxel - LIPAC Oncology

Next Previous
Drug Profile

Proliposomal paclitaxel - LIPAC Oncology

Alternative Names: LEIPC-1007; LEIPC-1008; LEITP-1009; LiPax; PLIP; TBC-1002; TSD 001; TSD 005; UTUC 1005

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TesoRx
  • Developer LIPAC Oncology; TesoRx
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bladder cancer
  • No development reported Mesothelioma; Ovarian cancer; Peritoneal cancer; Pleural effusion; Urogenital cancer

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for preclinical development in Mesothelioma in USA (Intrapleural)
  • 28 Mar 2025 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Intraperitoneal)
  • 28 Mar 2025 No recent reports of development identified for preclinical development in Peritoneal-cancer in USA (Intraperitoneal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top